
Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) – Analysts at Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for shares of Revelation Biosciences in a research report issued to clients and investors on Friday, November 6th. Zacks Research analyst B. Sorensen anticipates that the company will post earnings of ($4.71) per share for the quarter. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($24.53) per share. Zacks Research also issued estimates for Revelation Biosciences’ Q2 2027 earnings at ($4.10) EPS, Q3 2027 earnings at ($4.05) EPS and Q4 2027 earnings at ($4.92) EPS.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($5.92) earnings per share for the quarter, topping the consensus estimate of ($6.16) by $0.24.
Check Out Our Latest Stock Analysis on Revelation Biosciences
Revelation Biosciences Price Performance
Shares of NASDAQ:REVB opened at $4.33 on Thursday. The business has a fifty day moving average price of $5.16 and a 200-day moving average price of $7.42. The company has a market capitalization of $2.95 million, a PE ratio of -0.10 and a beta of -0.13. Revelation Biosciences has a 1-year low of $3.08 and a 1-year high of $40.60.
About Revelation Biosciences
Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases. Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.
Featured Articles
- Five stocks we like better than Revelation Biosciences
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
